SCHEMBL3016192

SCHEMBL3016192

Cc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4)CC3)n2)cc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 10/20 0.55
L3MBTL1 Q9Y468 5/20 0.55
ALDH1A1 P00352 5/20 0.55
MAPK1 P28482 4/20 0.53
NPC1 O15118 6/20 0.52
RAB9A P51151 6/20 0.52
MAPT P10636 5/20 0.50
USP2 O75604 1/20 0.50
RECQL P46063 1/20 0.50
HSD17B10 Q99714 1/20 0.50
AR P10275 2/20 0.48
HTT P42858 3/20 0.47
LMNA P02545 3/20 0.47
CYP1A2 P05177 3/20 0.46
CYP2C9 P11712 3/20 0.46
CYP2C19 P33261 3/20 0.46
CYP3A4 P08684 2/20 0.46
EGFR P00533 2/20 0.46
KMT2A Q03164 2/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007052 0.92 SMN1; SMN2 (0.53) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3006818 0.90 EGFR (0.48) SMN1; SMN2ALDH1A1MAPK1NPC1RAB9A
SCHEMBL3014731 0.90 SMN1; SMN2 (0.52) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3022723 0.89 RAB9A (0.47) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3001543 0.89 MAPK1 (0.50) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3014633 0.89 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3016139 0.88 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1MAPK1NPC1RAB9A
SCHEMBL3017057 0.88 SMN1; SMN2 (0.44) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3006219 0.88 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3016724 0.88 SMN1; SMN2 (0.54) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885L3MBTL1 1847/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.